[{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"NOUS-PEV","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nouscom AG \/ Not Applicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Not Applicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Not Applicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Not Applicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Not Applicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GAd20-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"ProBioGen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GAd20-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ ProBioGen","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ ProBioGen"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Series C Financing","leadProduct":"GAd20-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Andera Partners","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ Andera Partners"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Series C Financing","leadProduct":"NOUS-209","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Angelini Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Angelini Ventures"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"NOUS-209","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nouscom AG \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nouscom AG

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-209 is an off-the-shelf cancer vaccine, which is currently being evaluated for the treatment of mismatch repair/microsatellite instable metastatic colorectal cancer.

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 19, 2024

                          Lead Product(s) : NOUS-209,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Net proceeds will advance Nouscom's clinical pipeline, including readouts from a Phase 2 trial for NOUS-209, an off-the-shelf cancer vaccine for dMMR/MSI metastatic colorectal cancer.

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 21, 2024

                          Lead Product(s) : NOUS-209,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Angelini Ventures

                          Deal Size : $82.1 million

                          Deal Type : Series C Financing

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline, including NOUS-209 (GAd20-209-FSP), an off-the-shelf cancer vaccine targeting 209 shared neoantigens.

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 14, 2023

                          Lead Product(s) : GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Andera Partners

                          Deal Size : $72.0 million

                          Deal Type : Series C Financing

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting.

                          Brand Name : Nous-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 04, 2023

                          Lead Product(s) : GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : ProBioGen

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present ...

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : MSD Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-209 (GAd-209-FSP) is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors, generates highly immunogenic neoantigens called frame shift peptides (FSP) that are not present in healthy tissue.

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 15, 2022

                          Lead Product(s) : GAd-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : This mechanism was characterized in preclinical model of colorectal cancer and confirmed in Phase 1b trial in gastrointestinal patients with (MSI-H) tumors who saw durable clinical responses when treated with NOUS-209(GAd-209-FSP) in combination with ant...

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          August 11, 2022

                          Lead Product(s) : GAd-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-209 (GAd-209-FSP), is an off-the-shelf cancer vaccine targeting 209 shared neoantigens, in combination with anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of deficiency in Mismatch Repair/Microsatellite Instable HigH unresectable or...

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 06, 2022

                          Lead Product(s) : GAd-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-209 (GAd-209-FSP) is an off-the-shelf immunotherapy for Microsatellite Instable High (MSI-H) tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic frame shift peptides that are not found...

                          Brand Name : NOUS-209

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 27, 2022

                          Lead Product(s) : GAd-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NOUS-PEV will be investigated in the study as a potential treatment for patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC).

                          Brand Name : NOUS-PEV

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 11, 2021

                          Lead Product(s) : NOUS-PEV

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank